A. Ring

发表

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients

T. Heise, E. U. Graefe-Mody, K. Dugi, 2009, Diabetes, obesity & metabolism.

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

E. U. Graefe-Mody, K. Dugi, A. Ring, 2009, Current medical research and opinion.

Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.

A. Ring, T. Meinicke, C. Friedrich, 2013, Drug research.

A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio®) in cardiac surgery: the REVAKI‐1 study

N. Brunskill, W. Dott, A. Ring, 2017, British journal of clinical pharmacology.

How publication guidelines for clinical pharmacology trials may help to accelerate knowledge transfer

A. Ring, K. Breithaupt-Grögler, 2018, British journal of clinical pharmacology.

Bioequivalence of Glucophage ® (Metformin) Tablets from Europe and the United States Tested in Healthy Volunteers

A. Ring, C. Friedrich, T. Meinicke, 2014 .

Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach

C. Hemmelmann, R. Hilger, A. Ring, 2021, British journal of clinical pharmacology.

Pharmacokinetics of linagliptin in subjects with hepatic impairment.

H. Woerle, A. Ring, L. Waldhauser, 2012, British journal of clinical pharmacology.

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

J. Holst, T. Heise, H. Woerle, 2012, Diabetes Therapy.

Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

H. Woerle, K. Dugi, A. Ring, 2010, Diabetic medicine : a journal of the British Diabetic Association.

The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.

E. U. Graefe-Mody, K. Dugi, A. Ring, 2011, British journal of clinical pharmacology.

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin *

T. Heise, H. Woerle, H. Woerle, 2011, Diabetes, obesity & metabolism.

The potential of the estimands framework for clinical pharmacology trials: some discussion points.

A. Ring, M. Wolfsegger, 2020, British journal of clinical pharmacology.

Adding value to the experience of attending a diabetes clinic appointment: provision of personalised 10 year cardiovascular disease (CVD) risk estimates

R. Holman, H. Sourij, H. Price, 2013 .

Sample size determination in bioequivalence studies using statistical assurance

R. Schall, A. Ring, B. Lang, 2019, British journal of clinical pharmacology.

Delayed Effects in the Exposure-Response Analysis of Clinical QTc Trials

A. Ring, P. Glomb, 2012, Journal of biopharmaceutical statistics.

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5mg–10mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

U. Jaehde, K. Dugi, S. Hüttner, 2010, Clinical pharmacokinetics.

Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults

H. Woerle, A. Ring, A. Port, 2011, Clinical drug investigation.

A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.

H. Woerle, A. Ring, T. Giessmann, 2011, Clinical therapeutics.

Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.

K. Dugi, A. Ring, H. Stähle, 2010, International journal of clinical pharmacology and therapeutics.

Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation

R. Schall, A. Ring, 2011, Pharmaceutical statistics.

Ibuprofen Extrudate, a Novel, Rapidly Dissolving Ibuprofen Formulation: Relative Bioavailability Compared to Ibuprofen Lysinate and Regular Ibuprofen, and Food Effect on All Formulations

A. Ring, D. Trommeshauser, S. Scheuerer, 2005, Journal of clinical pharmacology.

Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

T. Macgregor, A. Ring, P. Robinson, 2008, Antimicrobial Agents and Chemotherapy.

Sensitivity of Empirical Metrics of Rate of Absorption in Bioequivalence Studies

L. Endrenyi, M. Weiss, A. Ring, 2000, Pharmaceutical Research.

Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model

W. Brannath, A. Ring, Susann Grill, 2020, Statistics in medicine.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

E. U. Graefe-Mody, K. Dugi, S. Hüttner, 2008, Journal of clinical pharmacology.

Evaluation of a Self-Administered Oral Glucose Tolerance Test

R. Holman, H. Sourij, H. Price, 2013, Diabetes Care.

Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects

A. Ring, A. Clemens, P. Reilly, 2013, Clinical Drug Investigation.

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

R. Califf, R. Holman, S. Paul, 2013, American heart journal.

Equivalence Tests in Subgroup Analyses

W. Brannath, R. Schall, A. Ring, 2018 .

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

U. Broedl, H. Woerle, A. Ring, 2013, Cardiovascular Diabetology.

The oral DPP‐4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

K. Dugi, A. Ring, T. Forst, 2011, Diabetes, obesity & metabolism.

Indirect bioequivalence assessment using network meta-analyses

R. Schall, K. Hohl, A. Ring, 2014, European Journal of Clinical Pharmacology.

Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.

H. Woerle, A. Ring, P. Rose, 2011, Drug metabolism and pharmacokinetics.

Cardiovascular toxicity, especially QT/QTc prolongation

R. Schall, A. Ring, 2014 .

Interpretation of general measures of distribution kinetics in terms of a mammillary compartmental model.

M. Weiss, A. Ring, 1997, Journal of pharmaceutical sciences.

Residuals and Outliers in Replicate Design Crossover Studies

Laszlo Endrenyi, Robert Schall, Arne Ring, 2010, Journal of biopharmaceutical statistics.

An efficient crossover design for thorough QT studies

A. Ring, D. Chanter, Beate Walter, 2010 .

Statistical models for heart rate correction of the QT interval

A. Ring, 2010, Statistics in medicine.

Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers

H. Woerle, E. U. Graefe-Mody, A. Ring, 2011, European Journal of Drug Metabolism and Pharmacokinetics.

Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

H. Woerle, K. Dugi, A. Ring, 2010, Diabetic medicine : a journal of the British Diabetic Association.

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin *

T. Heise, H. Woerle, A. Ring, 2011, Diabetes, obesity & metabolism.

Statistical Characterization of QT Prolongation

R. Schall, A. Ring, 2010, Journal of biopharmaceutical statistics.